Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jiaxun, Cai, Panpan, Li, Pengfei, Cao, Cong, Zhou, Jing, Dong, Lina, Yang, Yan, Xuan, Qijia, Wang, Jingxuan, Zhang, Qingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025815/
https://www.ncbi.nlm.nih.gov/pubmed/33806839
http://dx.doi.org/10.3390/curroncol28020126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025815/
https://www.ncbi.nlm.nih.gov/pubmed/33806839
http://dx.doi.org/10.3390/curroncol28020126

Ejemplares similares